Insider Purchases: Inside the Buy
Tag: Funanc1al Insider Series
Can LKQ Replace Bear Parts with Bull Run: Insiders Think So
Insiders are wrenching their way into LKQ stock, and institutions hold more shares than exist (!). With profits intact, dividends rolling, and valuation gauges flashing cheap, could this be the ultimate rebuild? Or is it just another jalopy on Wall Street’s lot? 🛠️📉➡️📈
BellRing Brands (BRBR): Insider Sips, Protein Shakes, and Market Jitters
BellRing Brands (BRBR), maker of Premier Protein and Dymatize, has insiders buying stock while institutions double down. Sales are up, but lawsuits, debt, and competition are shaking things up. Value play or value trap?
Western Union (WU): Cash Transfers, CEO Buys, and Maybe a Stock Rebound?
💸 Western Union’s CEO and CFO just wired big money into their own stock. Institutions already hold 95% of the float, but growth is flat, competition is fierce, and risks abound. Is this a bargain play — or a value trap in disguise?
Bakkt Holdings CEO Buys Shares; Are Profits Baked In?
Bakkt (BKKT) is back on the radar. With a new CEO buying $1.47M of stock and losses shrinking fast, is this crypto play baked to perfection—or half-baked hype?
Can Olin Cock Its Stock? Insiders Say Yes (Lock, Load, and Maybe Profit)
Olin ($OLN) insiders are loading up on shares while institutions already own 94% of the float. Profits are weak, ammo is hot, and bleach is… bleach. Can this 132-year-old company cock its stock for a rebound?
Elite Buys Ely: Should You Buy Lilly’s Stock Too?
Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?
Centene (CNC): CEO Buys at $25, Earnings Bleed Red, and the Stock’s on Life Support — Bargain or Bust?
Centene (CNC) just got a shot in the arm from its CEO and a director buying nearly $740K worth of stock near decade lows. But with Q2 earnings bleeding red, rising Medicaid costs, and valuation sliced in half, is this a bargain-bin opportunity or just a patient in the ICU?
How Many Insider Buys Will It Take for The Bull in Enphase Energy to Re-energize?
After a brutal drop, Enphase Energy’s CEO is buying big. Institutions are all in. Margins hold strong. Could this be the spark the solar bull needs?
COO Goes Shopping: Is Molina Healthcare (MOH) a Healthy Buy or Just a Check-Up?
When the COO of Molina Healthcare spends $1.56M on stock, investors notice. With Wall Street titans on board and shares at major support, is this a healthy buy — or a risky patient?
Can Elevance Reach Higher Elevations? The CEO Thinks So
📉 After falling nearly 50% from its highs, Elevance Health just got a $2.4M vote of confidence from its CEO. Is this the cure—or just another symptom? 🏥 Dive into the numbers, the risks, and the potential rewards. And yes, there will be icons. 📊💊📈